PET/MRI in Neuroendocrine Tumours: Blessings and Curses

Author(s): Mapelli Paola, De Cobelli F, Maria Picchio.

Journal Name: Current Radiopharmaceuticals

Volume 12 , Issue 2 , 2019

Become EABM
Become Reviewer

[1]
Yao, J.C.; Hassan, M.; Phan, A.; Dagohoy, C.; Leary, C.; Mares, J.E.; Abdalla, E.K.; Fleming, J.B.; Vauthey, J.N.; Rashid, A.; Evans, D.B. One hundred years after “carcinoid”: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol., 2008, 26, 3063-3072.
[2]
Wang, S.C.; Fidelman, N.; Nakakura, E.K. Management of well-differentiated gastrointestinal neuroendocrine tumors metastatic to the liver. Semin. Oncol., 2013, 40, 69-74.
[3]
Hope, T.A.; Pampaloni, M.H.; Nakakura, E.; VanBrocklin, H.; Slater, J.; Jivan, S.; Aparici, C.M.; Yee, J.; Bergsland, E. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdom. Imaging, 2015, 40, 1432-1440.
[4]
Sanli, Y.; Garg, I.; Kandathil, A.; Kendi, T.; Zanetti, M.J.B.; Kuyumcu, S.; Subramaniam, R.M. Neuroendocrine tumor diagnosis and management: (68)Ga-DOTATATE PET/CT. AJR Am. J. Roentgenol., 2018, 211(2), 267-277.
[5]
Beiderwellen, K.J.; Poeppel, T.D.; Hartung-Knemeyer, V.; Buchbender, C.; Kuehl, H.; Bockisch, A.; Lauenstein, T.C. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: Initial results. Invest. Radiol., 2013, 48, 273-279.
[6]
Dromain, C.; de Baere, T.; Lumbroso, J.; Caillet, H.; Laplanche, A.; Boige, V.; Ducreux, M.; Duvillard, P.; Elias, D.; Schlumberger, M.; Sigal, R.; Baudin, E. Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J. Clin. Oncol., 2005, 23, 70-78.
[7]
Kim, Y.K.; Lee, M.W.; Lee, W.J.; Kim, S.H.; Rhim, H.; Lim, J.H.; Choi, D.; Kim, Y.S.; Jang, K.M.; Lee, S.J.; Lim, H.K. Diagnostic accuracy and sensitivity of diffusion-weighted and of gadoxetic acid-enhanced 3-T MR imaging alone or in combination in the detection of small liver metastasis (</= 1.5 cm in diameter). Invest. Radiol., 2012, 47, 159-166.
[8]
Werner, R.A.; Solnes, L.B.; Javadi, M.S.; Weich, A.; Gorin, M.A.; Pienta, K.J.; Higuchi, T.; Buck, A.K.; Pomper, M.G.; Rowe, S.P.; Lapa, C. SSTR-RADS version 1.0 as a reporting system for SSTR PET imaging and selection of potential PRRT candidates: A proposed standardization framework. J. Nucl. Med., 2018, 59, 1085-1091.
[9]
Donati, O.F.; Reiner, C.S.; Hany, T.F.; Fornaro, J.; von Schulthess, G.K.; Marincek, B.; Weishaupt, D. 18F-FDG-PET and MRI in patients with malignancies of the liver and pancreas. Accuracy of retrospective multimodality image registration by using the CT-component of PET/CT. Nuklearmedizin, 2010, 49, 106-114.
[10]
Antoch, G.; Vogt, F.M.; Freudenberg, L.S.; Nazaradeh, F.; Goehde, S.C.; Barkhausen, J.; Dahmen, G.; Bockisch, A.; Debatin, J.F.; Ruehm, S.G. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. Jama, 2003, 290, 3199-3206.
[11]
Samarin, A.; Burger, C.; Wollenweber, S.D.; Crook, D.W.; Burger, I.A.; Schmid, D.T.; von Schulthess, G.K.; Kuhn, F.P. PET/MR imaging of bone lesions--implications for PET quantification from imperfect attenuation correction. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39, 1154-1160.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 12
ISSUE: 2
Year: 2019
Page: [96 - 97]
Pages: 2
DOI: 10.2174/1874471012999190404151701

Article Metrics

PDF: 25
HTML: 10
EPUB: 1
PRC: 1